Radiolabelled Peptides: Optimal Candidates for Theranostic Application in Oncology

被引：7

作者：

Hall, Andrew J. ^{[1
]}

Haskali, Mohammad B. ^{[1
,2
]}

机构：

[1] Peter MacCallum Canc Ctr, Radiopharmaceut & Res Lab, Melbourne, Vic 3000, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3010, Australia

来源：

AUSTRALIAN JOURNAL OF CHEMISTRY | 2022年 / 75卷 / 02期

基金：

英国医学研究理事会;

关键词：

theranostic; radiopharmaceutical; radiolabelling; peptide; foldamers; oncology; RNT; PET; PRRT; radionuclide; ONE-STEP RADIOSYNTHESIS; METAL-ION COMPLEXES; LANTHANIDE COMPLEXES; CYCLOTRON PRODUCTION; PROSTATE-CANCER; IMAGING AGENTS; AUTOMATED PREPARATION; SOMATOSTATIN ANALOGS; RECEPTOR EXPRESSION; METABOLIC STABILITY;

D O I：

10.1071/CH21118

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Theranostics are drugs suitable for use in both diagnostic and therapeutic applications, and have played an important role in the advancement of modern nuclear medicine. This review explains key elements that are common to successful theranostics and highlights significant developments in the field, including our own. Specific focus is given to peptides and those features that make them most suitable for theranostic application, as well as some key radioisotopes owing to their favourable properties and high clinical utility. This report provides an overview of the techniques at the researcher's disposal, how they have been applied to current clinically significant targets, and how they might be used and improved upon for future targets.

引用

页码：34 / 54

页数：21

共 197 条

[11] PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer [J].

Baranski, Ann-Christin ;

Schaefer, Martin ;

Bauder-Wuest, Ulrike ;

Roscher, Mareike ;

Schmidt, Jana ;

Stenau, Esther ;

Simpfendoerfer, Tobias ;

Teber, Dogu ;

Maier-Hein, Lena ;

Hadaschik, Boris ;

Haberkorn, Uwe ;

Eder, Matthias ;

Kopka, Klaus .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (04) :639-645

[12] Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties [J].

Baranski, Ann-Christin ;

Schaefer, Martin ;

Bauder-Wuest, Ulrike ;

Wacker, Anja ;

Schmidt, Jana ;

Liolios, Christos ;

Mier, Walter ;

Haberkorn, Uwe ;

Eisenhut, Michael ;

Kopka, Klaus ;

Eder, Matthias .

BIOCONJUGATE CHEMISTRY, 2017, 28 (09) :2485-2492

[13]

BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X

[14]

Be M., 2004, TABLE RADIONUCLIDES

[15]

Be M.-M., 2016, TABLE RADIONUCLIDES

[16]

Béhé M, 2005, J NUCL MED, V46, P1012

[17]

Behr TM, 1999, J NUCL MED, V40, P1029

[18] Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile [J].

Benesova, Martina ;

Umbricht, Christoph A. ;

Schibli, Roger ;

Muller, Cristina .

MOLECULAR PHARMACEUTICS, 2018, 15 (03) :934-946

[19] Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors [J].

Benesova, Martina ;

Bauder-Wuest, Ulrike ;

Schaefer, Martin ;

Klika, Karel D. ;

Mier, Walter ;

Haberkorn, Uwe ;

Kopka, Klaus ;

Eder, Matthias .

JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (05) :1761-1775

[20] Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer [J].

Benesova, Martina ;

Schaefer, Martin ;

Bauder-Wuest, Ulrike ;

Afshar-Oromieh, Ali ;

Kratochwil, Clemens ;

Mier, Walter ;

Haberkorn, Uwe ;

Kopka, Klaus ;

Eder, Matthias .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (06) :914-920

← 1 2 3 4 5 6 7 8 9 10 →